Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise

Share Article

Progyny Raises New Round to Fund Clinical Solutions that Improve Patient Outcomes

News Image

Progyny, Inc., the new combined entity of Auxogyn, Inc. and Fertility Authority, LLC, announced that it has secured additional capital from investors including Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech, SR One and Merck Serono Ventures. The funding will enable the company to accelerate efforts to provide patients the best fertility outcomes by aligning science, technology, clinics and patients.

Progyny is the largest online marketplace for families seeking fertility solutions and we are committed to helping patients take control of their fertility journey,“ said Gina Bartasi, chief executive officer. “We are able to provide fertility patients an end-to-end experience where they are empowered to select a physician from our elite network of fertility doctors offering exclusive pricing, build a customized fertility health plan and make a purchase with the ease of a few clicks.”

The all-inclusive, easy-to-use digital platform provides patients access to high quality doctors, price transparency and financing, coupled with extraordinary clinical expertise and proprietary clinical solutions. Patients are guided through the fertility health journey and provided expert data on important health issues including elective egg freezing, IVF treatment options, and the Eeva™ Test. The Eeva™ Test is a first-in-class FDA cleared non-invasive prognostic test that uses time-lapse imaging and statistical modeling to consistently and objectively assess early embryo development milestones with minimal disturbance to the embryos during incubation. The proprietary, automated Eeva Test helps IVF clinicians optimize their treatment for patients undergoing IVF procedures.

“We are pleased to have the support of leading healthcare investors,” said Darrin Uecker, president and chief operating officer. “We are now uniquely positioned for rapid expansion by deeply understanding fertility patients and delivering proprietary solutions to clinics that will improve fertility outcomes.”

Progyny’s portfolio of solutions incudes:, the country’s leading patient-matching technology platform serving the fertility industry;, a national network of over 185 top fertility doctors specializing in egg freezing; and, the only multi-cycle IVF savings program created by patients for patients; and The Eeva™ Test.

About The Company:
Progyny, the combined entity of Auxogyn, Inc. and Fertility Authority LLC, is the first company to provide fertility patients with easy accessibility to high quality doctors, price transparency, and financing, coupled with extraordinary clinical expertise and proprietary clinical solutions. Rooted in clinical expertise and serving as a champion for the consumer, the company is committed to helping ensure that patients control their fertility journey and achieve the best possible outcome. Progyny is privately held and it’s investors include Kleiner Perkins Caufield & Byers, TPG Biotech, SR One, and Merck Serono Ventures. The company is headquartered in New York, NY with operations in Menlo Park, CA.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robin McCarthy
Email >
Follow us on